Transcode Therapeutics Inc (RNAZ) — Financial Flexibility Index
Transcode Therapeutics Inc (RNAZ) has a Financial Flexibility Index of -0.05x as of March 2026. Free cash flow of $-8.14 Million (operating CF $-8.14 Million minus capex $6.66K) represents 0% of total liabilities ($152.06 Million). Check how strategically is Transcode Therapeutics Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Transcode Therapeutics Inc Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for Transcode Therapeutics Inc across 8 annual periods. See Transcode Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Transcode Therapeutics Inc (2018–2025)
Year-by-year free cash flow to debt coverage for Transcode Therapeutics Inc. For the full company profile including market capitalisation, see market value of Transcode Therapeutics Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.13x | $-19.51 Million | $-19.52 Million | $152.06 Million | ▲ +91.0% |
| 2024 | -1.43x | $-13.31 Million | $-13.34 Million | $9.31 Million | ▲ +72.0% |
| 2023 | -5.11x | $-18.04 Million | $-18.07 Million | $3.53 Million | ▼ -41.9% |
| 2022 | -3.60x | $-15.66 Million | $-15.76 Million | $4.35 Million | ▼ -82.1% |
| 2021 | -1.98x | $-5.01 Million | $-5.27 Million | $2.53 Million | ▼ -3607.0% |
| 2020 | -0.05x | $-238.15K | $-492.97K | $4.46 Million | ▲ +72.4% |
| 2019 | -0.19x | $-253.69K | $-508.51K | $1.31 Million | ▼ -210.0% |
| 2018 | -0.06x | $-44.75K | $-299.57K | $718.61K | — |